ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial h
ARWR Arrowhead Pharmaceuticals completes enrollment in global phase 3 yosemite study of zodasiran for the treatment of homozygous familial hypercholesterolemia Arrowhead Pharmaceuticals - yosemite phase 3 study completion anticipated in mid-2027